4DX Stock Overview
A biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pluri Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.60 |
| 52 Week High | US$7.32 |
| 52 Week Low | US$3.10 |
| Beta | 1.52 |
| 1 Month Change | 0% |
| 3 Month Change | 3.70% |
| 1 Year Change | 3.70% |
| 3 Year Change | -76.38% |
| 5 Year Change | -87.80% |
| Change since IPO | -76.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -1.0% |
| 1Y | 3.7% | -25.9% | 6.4% |
Return vs Industry: 4DX exceeded the German Biotechs industry which returned -25.9% over the past year.
Return vs Market: 4DX underperformed the German Market which returned 6.4% over the past year.
Price Volatility
| 4DX volatility | |
|---|---|
| 4DX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4DX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 4DX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 129 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.
Pluri Inc. Fundamentals Summary
| 4DX fundamental statistics | |
|---|---|
| Market cap | €30.64m |
| Earnings (TTM) | -€19.92m |
| Revenue (TTM) | €314.23k |
97.5x
P/S Ratio-1.5x
P/E RatioIs 4DX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DX income statement (TTM) | |
|---|---|
| Revenue | US$341.00k |
| Cost of Revenue | US$9.00k |
| Gross Profit | US$332.00k |
| Other Expenses | US$21.95m |
| Earnings | -US$21.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.01 |
| Gross Margin | 97.36% |
| Net Profit Margin | -6,339.59% |
| Debt/Equity Ratio | 1,304.3% |
How did 4DX perform over the long term?
See historical performance and comparison